He Siyuan, Guo Qi, Zhao Lan, Xu Liyun, Fan Junsheng, Wu Wenye, Zhang Zhemin, Li Bing, Chu Haiqing
Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
School of Medicine, Tongji University, Shanghai, China.
Front Microbiol. 2022 Jan 6;12:779531. doi: 10.3389/fmicb.2021.779531. eCollection 2021.
Therapeutic options for treating infections are extremely limited; quinolones are important. The anti- activities of nine quinolones, emphasizing sitafloxacin, were investigated. Antimicrobial susceptibility testing was performed on 10 non-tuberculous mycobacterium reference strains and 194 clinical, isolates. The activity of sitafloxacin against intracellular residing within macrophages was also evaluated. A checkerboard assay was conducted to determine synergy between sitafloxacin and 10 clinically important antibiotics. Among the nine quinolones tested, sitafloxacin exhibited the greatest anti- activity with MIC and MIC of 1 and 2 mg/L, respectively. Sitafloxacin exerted a bacteriostatic effect on and inhibited the intracellular growth of at concentrations equivalent to clarithromycin. No antagonism between sitafloxacin and 10 clinically important anti- antibiotics was evident. In summary, sitafloxacin exhibited a significant advantage relative to other quinolones in inhibiting the growth of , suggesting the potential inclusion of sitafloxacin in new strategies to treat infections.
治疗感染的选择极其有限；喹诺酮类药物很重要。对九种喹诺酮类药物的抗菌活性进行了研究，重点是西他沙星。对10株非结核分枝杆菌参考菌株和194株临床分离株进行了药敏试验。还评估了西他沙星对巨噬细胞内寄生菌的活性。进行棋盘法试验以确定西他沙星与10种临床重要抗生素之间的协同作用。在所测试的九种喹诺酮类药物中，西他沙星表现出最强的抗菌活性，其MIC和MIC分别为1mg/L和2mg/L。西他沙星对该菌发挥抑菌作用，并在与克拉霉素相当的浓度下抑制其细胞内生长。西他沙星与10种临床重要抗菌药物之间未发现明显拮抗作用。总之，西他沙星在抑制该菌生长方面相对于其他喹诺酮类药物具有显著优势，表明西他沙星有可能被纳入治疗该菌感染的新策略中。
